drugset

drugset / Trial / NCT04976309

A Single Dose Study of Lu AG09222 in a Headache Model With Healthy Subjects

NCT04976309 ↗

Phase 1 Completed 25 enrolled H. Lundbeck A/S

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate how well Lu AG09222 can prevent blood vessel dilation in a headache model.

Timeline

Start: 2021-07-15
Primary completion: 2021-09-19
Completion: 2021-12-10

Publications

Rasmussen NB, Deligianni C, Christensen CE, Karlsson WK, Al-Khazali HM, Van de Casteele T, Granhall C, Amin FM, Ashina M. The effect of Lu AG09222 on PACAP38- and VIP-induced vasodilation, heart rate increase, and headache in healthy subjects: an interventional, randomized, double-blind, parallel-group, placebo-controlled study. J Headache Pain. 2023 May 25;24(1):60. doi: 10.1186/s10194-023-01599-w.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Lu AG09222	Monoclonal antibody	—	Intravenous

Indications

No indication recorded.